Buprenorphine and Paliperidone: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Paliperidone
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Buprenorphine (a pain or addiction medicine) and paliperidone (Invega, used for certain mental health conditions) can affect your body in two overlapping ways when taken together.
First, both can slow down your heart's electrical rhythm (called QT prolongation), which in rare cases can trigger a dangerous heartbeat. Second, both can have a calming effect on the brain, so together they may make you extra sleepy, dizzy, or slow to react. This warning is based on how these drugs work rather than proven cases, but it is taken seriously. The good news: your care team can manage this safely by choosing the right plan and watching you closely. Never stop or change either medicine on your own, just talk with your pharmacist or doctor.
Effect: Additive risk of QT interval prolongation and torsade de pointes, plus additive CNS depression, when buprenorphine is combined with paliperidone.
Mechanism: Both agents can prolong the QT interval; both have central depressant activity. Purely pharmacodynamic (no prodrug considerations relevant here).
- Direction: Additive/increased effect of both toxicities.
- Onset: Unspecified.
- Evidence: Theoretical; magnitude not quantified.
- Management: Avoid concomitant use where possible. If combined, correct electrolytes (K+, Mg2+), obtain baseline/follow-up ECG, and assess additional risk factors (bradycardia, HF, baseline QT prolongation, congenital long-QT). Monitor for excessive sedation/respiratory depression.
What happens
An increased risk of CNS depression, an increased risk of QT interval prolongation and torsade de pointes
Interaction Deep Dive
The combined use of buprenorphine with agents capable of prolonging the QT interval, paliperidone among them, should be avoided 3425. Using them together may raise the likelihood of torsades de pointes and/or sudden death. Administering paliperidone alongside centrally acting agents can additionally heighten the risk of CNS depression 5. It remains unknown what risk arises from pairing buprenorphine with other agents that prolong QT. When prescribing buprenorphine to patients presenting with risk factors, including hypokalemia, bradycardia, recent conversion from atrial fibrillation, congestive heart failure, digitalis therapy, baseline QT prolongation, subclinical long-QT syndrome, or severe hypomagnesemia, these considerations should factor into clinical decisions 1.
Why it happens (mechanism)
Additive QT interval prolongation; additive CNS depression
How to manage this interaction
Both medicines can add up to affect your heart rhythm and your alertness, so your care team may prefer to avoid this combination or manage it carefully.
- Keep taking both exactly as prescribed unless your prescriber tells you otherwise.
- Your team may check an ECG and your potassium and magnesium levels, and monitor you more closely.
- Tell your prescriber if you have heart conditions, a slow heartbeat, heart failure, or a family history of rhythm problems.
- Report fainting, palpitations, severe drowsiness, or trouble breathing right away.
Ask your pharmacist or doctor whether an alternative is a better fit for you.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Buprenorphine and Paliperidone together?
Combining buprenorphine and paliperidone can add up to raise the risk of a dangerous heart rhythm and excessive sedation, so this pairing is often avoided; keep taking both as prescribed and let your care team decide on monitoring or an alternative. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Paliperidone interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Paliperidone interaction managed?
Both medicines can add up to affect your heart rhythm and your alertness, so your care team may prefer to avoid this combination or manage it carefully. Keep taking both exactly as prescribed unless your prescriber tells you otherwise. Your team may check an ECG and your potassium and magnesium levels, and monitor you more closely. Tell your prescriber if you have heart conditions, a slow heartbea… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Buprenorphine or Paliperidone need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (5)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: BUTRANS(R) transdermal system patch, buprenorphine transdermal system patch. Purdue Pharma L.P. (per FDA), Stamford, CT, 2016. DailyMed
- Product Information: BELBUCA(TM) buccal film, buprenorphine buccal film. Endo Pharmaceuticals Inc. (per FDA), Malvern, PA, 2016.
- Product Information: BUPRENEX(R) intravenous injection, intramuscular injection, buprenorphine HCl intravenous injection, intramuscular injection. Indivior Inc. (per DailyMed), Richmond, VA, 2016. DailyMed
- Product Information: ERZOFRI(R) intramuscular extended-release injectable suspension, paliperidone palmitate intramuscular extended-release injectable suspension. Luye Pharma (USA) Ltd (per FDA), Princeton, NJ, 2024.
Keep reading about Buprenorphine
Keep reading about Paliperidone
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist